Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $22.5 million.

  • Lifecore Biomedical's Cost of Revenue rose 8.96% to $22.5 million in Q2 2025 from the same period last year, while for May 2025 it was $88.6 million, marking a year-over-year increase of 2.50%. This contributed to the annual value of $88.6 million for FY2025, which is 2.50% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Cost of Revenue is $22.5 million, which was down 11.25% from $25.3 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical's Cost of Revenue peaked at $25.3 million during Q1 2025, and registered a low of -$27.7 million during Q2 2022.
  • Its 3-year average for Cost of Revenue is $21.6 million, with a median of $21.6 million in 2023.
  • As far as peak fluctuations go, Lifecore Biomedical's Cost of Revenue tumbled by 288.91% in 2022, and later spiked by 184.37% in 2023.
  • Over the past 5 years, Lifecore Biomedical's Cost of Revenue (Quarterly) stood at $14.1 million in 2021, then grew by 14.44% to $16.2 million in 2022, then grew by 24.76% to $20.2 million in 2023, then rose by 6.37% to $21.5 million in 2024, then increased by 8.96% to $22.5 million in 2025.
  • Its Cost of Revenue was $22.5 million in Q2 2025, compared to $25.3 million in Q1 2025 and $21.5 million in Q4 2024.